Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Une étude de phase III sur l'HMPL-760 en association avec R-GemOx contre un placebo en association avec R-GemOx dans le lymphome diffus à grandes cellules B récidivant/réfractaire

9 novembre 2026 mis à jour par: Hutchmed

Étude randomisée de phase III, en double aveugle, contrôlée positivement, évaluant l'efficacité, la sécurité et la pharmacocinétique de HMPL-760 en association avec R-GemOx par rapport au placebo en association avec R-GemOx chez des patients atteints de lymphome diffus à grandes cellules B (DLBCL) en rechute/réfractaire

This is a Phase III randomized, double-blind, positive controlled study to evaluate the efficacy, safety, and pharmacokinetics of HMPL-760 in combination with R-GemOx versus placebo in combination with R-GemOx in patients with R/R DLBCL.

Aperçu de l'étude

Description détaillée

The study phases include screening period, treatment period, safety observation period, PFS follow-up period, and OS follow-up period.

The target population of this study includes patients with DLBCL who are relapsed or refractory.

Type d'étude

Interventionnel

Inscription (Estimé)

240

Phase

  • Phase 3

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Lieux d'étude

      • Baoding, Chine
        • Recrutement
        • Baoding NO.1 Central Hospital
        • Contact:
        • Chercheur principal:
          • Haiying Yao
      • Beijing, Chine
        • Recrutement
        • Beijing GoBroad Hospital
        • Chercheur principal:
          • Kai Hu
        • Contact:
      • Beijing, Chine
        • Recrutement
        • BEIJING TONGREN HOSPITAL, Capital Medical University
        • Chercheur principal:
          • Liang Wang
        • Contact:
      • Bengbu, Chine
        • Recrutement
        • The First Affiliated Hospital of Bengbu Medical College
        • Contact:
        • Chercheur principal:
          • Yanli Yang
      • Changchun, Chine
        • Recrutement
        • The First Hospital of Jilin University
        • Chercheur principal:
          • Ou Bai
        • Contact:
      • Changsha, Chine
        • Recrutement
        • Hunan Cancer Hospital
        • Chercheur principal:
          • Hui Zhou
        • Contact:
      • Changsha, Chine
        • Recrutement
        • The Second Xiangya Hospital of Central South University
        • Chercheur principal:
          • Hongling Peng
        • Contact:
      • Changsha, Chine
        • Recrutement
        • People's Hospital of Hunan Province
        • Contact:
        • Chercheur principal:
          • Can Liu
      • Chengdu, Chine
        • Recrutement
        • West China Hospital of Sichuan University
        • Chercheur principal:
          • Liqun Zou
        • Contact:
      • Chengdu, Chine
        • Recrutement
        • Sichuan Provincial People's Hospital
        • Contact:
        • Chercheur principal:
          • Xiaobing Huang
      • Chongqing, Chine
        • Recrutement
        • The First Affiliated Hospital of Chongqing Medical University
        • Chercheur principal:
          • Xin Wang
        • Contact:
      • Chongqing, Chine
        • Recrutement
        • Chongqing University Cancer Hospital
        • Chercheur principal:
          • Yao Liu
        • Contact:
      • Fujian, Chine
        • Recrutement
        • Quanzhou First Hospital.Fujian
        • Contact:
        • Chercheur principal:
          • Xiongpeng Zhu
      • Fuzhou, Chine
        • Recrutement
        • Fujian Medical University Union Hospital
        • Chercheur principal:
          • Jianzhen Shen
        • Contact:
      • Guangzhou, Chine
        • Recrutement
        • Sun Yat-sen University Cancer Center
        • Chercheur principal:
          • Zhiming Li
        • Contact:
      • Guangzhou, Chine
        • Recrutement
        • Guangdong Provincial People's Hospital
        • Contact:
        • Chercheur principal:
          • Xiaojuan Wei
      • Guangzhou, Chine
        • Recrutement
        • ZhuJiang Hospital of Southern Medical University(The Second Clinical Medical College)
        • Chercheur principal:
          • Yuhua Li
        • Contact:
      • Guiyang, Chine
        • Recrutement
        • The Affiliated Hospital of Guizhou Medical University
        • Chercheur principal:
          • Yan Zhang
        • Contact:
      • Hangzhou, Chine
        • Recrutement
        • Zhejiang Cancer Hospital
        • Chercheur principal:
          • Haiyan Yang
        • Contact:
      • Hangzhou, Chine
        • Recrutement
        • The First Affiliated Hospital, Zhejiang University
        • Chercheur principal:
          • Zhen Cai
        • Contact:
      • Harbin, Chine
        • Recrutement
        • Harbin Medical University Cancer Hospital
        • Contact:
        • Chercheur principal:
          • Qingyuan Zhang
      • Hefei, Chine
        • Recrutement
        • The Second Affiliated Hospital of Anhui Medical University
        • Contact:
        • Chercheur principal:
          • Zhimin Zhai
      • Jinan, Chine
        • Recrutement
        • Qilu Hospital of Shandong University
        • Contact:
        • Chercheur principal:
          • Shuqian Xu
      • Jinan, Chine
        • Recrutement
        • Shandong Cancer Hospital & Institute
        • Chercheur principal:
          • Zengjun Li
        • Contact:
      • Kunming, Chine
        • Pas encore de recrutement
        • The First Affiliated Hospital of Kunming Medical University
        • Contact:
        • Chercheur principal:
          • Mingxia Shi
      • Nanchang, Chine
        • Recrutement
        • Jiangxi Cancer Hospital
        • Chercheur principal:
          • Yan Huang
        • Contact:
      • Nanjing, Chine
        • Recrutement
        • Jiangsu Cancer Hospital
        • Chercheur principal:
          • Yan Zhang
        • Contact:
      • Nanjing, Chine
        • Recrutement
        • Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School
        • Contact:
        • Chercheur principal:
          • Jingyan Xu
      • Nanning, Chine
        • Recrutement
        • The First Affiliated Hospital of Guangxi Medical University
        • Chercheur principal:
          • Zhigang Peng
        • Contact:
      • Qingdao, Chine
        • Recrutement
        • The Affiliated Hospital of Qingdao University
        • Contact:
        • Chercheur principal:
          • Xia Zhao
      • Shanghai, Chine
        • Recrutement
        • Ruijin Hospital, Shanghai Jiaotong University School of Medicine
        • Chercheur principal:
          • Weili Zhao
        • Contact:
      • Shanghai, Chine
        • Recrutement
        • Tongji Hospital of Tongji University
        • Contact:
        • Chercheur principal:
          • Ping Li
      • Shanghai, Chine
        • Pas encore de recrutement
        • Tong Ren Hospital Shanghai Jiao Tong University School Of Medicine
        • Chercheur principal:
          • Ligen Liu
        • Contact:
      • Shenyang, Chine
        • Recrutement
        • Shengjing Hospital of China Medical University
        • Chercheur principal:
          • Wei Yang
        • Contact:
      • Shenzhen, Chine
        • Recrutement
        • Shenzhen people's hospital
        • Chercheur principal:
          • Jihao Zhou
        • Contact:
      • Taiyuan, Chine
        • Recrutement
        • Shanxi Provincial Cancer Hospital
        • Chercheur principal:
          • Liping Su
        • Contact:
      • Tangshan, Chine
        • Recrutement
        • North China University of Science and Technology Affiliated Hospital
        • Contact:
        • Chercheur principal:
          • Zhenyu Yan
      • Tianjin, Chine
        • Recrutement
        • Tianjin Medical University Cancer Institute & Hospital
        • Chercheur principal:
          • Zhengzi Qian
        • Contact:
          • Zhengzi Qian
          • Numéro de téléphone: 13702031222
          • E-mail: qzz@163.com
      • Tianjin, Chine
        • Recrutement
        • Tianjin People's Hospital
        • Contact:
        • Chercheur principal:
          • Xingli Zhao
      • Tianjin, Chine
        • Recrutement
        • Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
        • Chercheur principal:
          • Dehui Zou
        • Contact:
      • Wenzhou, Chine
        • Recrutement
        • The First Affiliated Hospital of WMU
        • Contact:
        • Chercheur principal:
          • Songfu Jiang
      • Wuhan, Chine
        • Recrutement
        • Hubei Cancer Hospital
        • Chercheur principal:
          • Huijing Wu
        • Contact:
      • Wuhan, Chine
        • Recrutement
        • Wuhan Union Hospital of China
        • Chercheur principal:
          • Liling Zhang
        • Contact:
      • Xi'an, Chine
        • Recrutement
        • The First Affiliated Hospital of Xi'an Jiaotong University
        • Chercheur principal:
          • Pengcheng He
        • Contact:
      • Xi'an, Chine
        • Recrutement
        • The Second Affiliated Hospital of Xi'an Jiaotong University (Xibei Hosiptal)
        • Chercheur principal:
          • Jie Liu
        • Contact:
      • Xiamen, Chine
        • Pas encore de recrutement
        • The First Affiliated Hospital of Xiamen University
        • Chercheur principal:
          • Bing Xu
        • Contact:
      • Xuzhou, Chine
        • Recrutement
        • The Affiliated Hospital of Xuzhou Medical University
        • Contact:
        • Chercheur principal:
          • Wei Sang
      • Zhengzhou, Chine
        • Recrutement
        • Henan Cancer Hospital
        • Chercheur principal:
          • Keshu Zhou
        • Contact:
      • Zhengzhou, Chine
        • Recrutement
        • The First Affiliated Hospital of Zhengzhou University
        • Contact:
        • Chercheur principal:
          • Xudong Zhang
      • Ürümqi, Chine
        • Recrutement
        • People's Hospital of Xinjiang Uygur Autonomous Region
        • Chercheur principal:
          • Yan Li
        • Contact:
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Chine
        • Recrutement
        • Fudan University Shanghai Cancer Center
        • Contact:
          • Fangfang Lv
          • Numéro de téléphone: 18017312613
          • E-mail: Lvff80@163.com
        • Chercheur principal:
          • Fangfang Lv

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  1. Sign the ICF and be able to follow the requirements of study protocol;
  2. Age ≥18 years;
  3. ECOG performance status score between 0 and 2;
  4. Histopathologically confirmed diagnosis of DLBCL;
  5. The investigator judges that the patient's current condition requires further treatment;
  6. Patients should have at least one bi-dimensionally measurable lesion;
  7. Expected survival is more than 12 weeks;

Exclusion Criteria:

  1. Patients with known primary or secondary central nervous system lymphoma (CNSL) or the presence of clinical symptoms suggestive of CNSL;
  2. Women who are pregnant (positive pregnancy test during the screening period) or breastfeeding;
  3. Organ insufficiency;
  4. Currently known history of liver disease, including cirrhosis, alcoholic liver, known active infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV);
  5. History of significant organ bleeding, including gastrointestinal bleeding, hematencephalon, haemoptysis, etc., within 8 weeks prior to the first dose of study drug;
  6. Known risk of bleeding, such as coagulation factor deficiency, vascular hemophilia; or the patient is receiving vitamin K antagonist (warfarin);
  7. The toxic reactions of previous anti-tumor therapy have not recovered to the level of ≤ grade 1 (except for alopecia and decreased appetite and other conditions that have been clearly required in the inclusion and exclusion criteria);
  8. Clinically significant active infection;

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Quadruple

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: The experimental group

Patients will receive HMPL-760 once daily (QD) orally in combination with R-GemOx regimen in 21-day cycles for a total of 8 cycles. Rituximab 375 mg/m2 IV is given on Day 1 of each cycle, and gemcitabine 1000 mg/m2 IV followed by oxaliplatin 100 mg/m2 IV is given on Day 2 of each cycle.

Patients will receive HMPL-760 once daily (QD) orally.

R-GemOx regimen in 21-day cycles for a total of 8 cycles. Rituximab 375 mg/m2 IV is given on Day 1 of each cycle, and gemcitabine 1000 mg/m2 IV followed by oxaliplatin 100 mg/m2 IV is given on Day 2 of each cycle.

Autres noms:
  • Chlorhydrate de gemcitabine pour injection
  • Injection de rituximab
  • Injection d'Oxaliplatine
Comparateur placebo: The control group

Placebo QD at the same dose as HMPL-760 in the experimental group will be given in the control group, and the combination therapy is the same as in the experimental group.

R-GemOx regimen in 21-day cycles for a total of 8 cycles. Rituximab 375 mg/m2 IV is given on Day 1 of each cycle, and gemcitabine 1000 mg/m2 IV followed by oxaliplatin 100 mg/m2 IV is given on Day 2 of each cycle.

Autres noms:
  • Chlorhydrate de gemcitabine pour injection
  • Injection de rituximab
  • Injection d'Oxaliplatine

Patients will receive HMPL-760 placebo once daily (QD) orally.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Progression-free survival (PFS)
Délai: Up to approximately two years

Investigator-assessed progression-free survival (PFS) Efficacy is evaluated using the Lugano Efficacy Evaluation Criteria for Malignant Lymphoma (Cheson 2014). PFS is defined as the time from randomization to PD or death due to any cause, whichever occurs first.

Up to approximately two years
End of treatment (EOT)
Délai: Up to approximately two years

Tumor assessment data will continue to be collected. Tumor assessment data collected after end of treatment (EOT) will be used. Tumor assessment data collected during the study and after EOT will be included in the PFS analysis (treatment policy strategy).

Up to approximately two years
Systemic antitumor therapy
Délai: Up to approximately two years

Use of other systemic antitumor therapy before PD or death (in the absence of PD):Tumor assessment after use of other systemic antitumor therapy will not be included in the analysis. For patients using other anti-tumor therapy before PD or death (in absence of PD), PFS will be censored at the last evaluable tumor assessment before the use of other systematic anti-tumor therapy (hypothetical strategy).

Up to approximately two years
Overall survival (OS)
Délai: Up to approximately two years

OS is defined as the time from randomization to death due to any cause.

Up to approximately two years
systematic anti-tumor therapy
Délai: Up to approximately two years

OS data will continue to be collected after the other systematic anti-tumor therapy, and the OS data collected before and after other systematic anti-tumor therapy will be included in analysis (treatment policy strategy).

Up to approximately two years
Premature withdrawal from study treatment
Délai: Up to approximately two years

OS data will continue to be collected after the patient's premature withdrawal from study treatment, and the OS data collected during the study treatment and after EOT will be included in analysis (treatment policy strategy).

Up to approximately two years

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Independent review committee (IRC)-assessed PFS
Délai: Up to approximately two years

Efficacy is evaluated using the Lugano Efficacy Evaluation Criteria for Malignant Lymphoma (Cheson 2014).

Up to approximately two years
IRC- and investigator-assessed objective response rate (ORR)
Délai: Up to approximately two years

Objective Response Rate (ORR) is defined as the ratio of patients who reached complete response (CR) or partial response (PR)

Up to approximately two years
IRC- and investigator-assessed complete response rate (CRR)
Délai: Up to approximately two years

Complete response (CR) rate is defined as the ratio of patients with who reached complete response (CR)

Up to approximately two years
IRC- and investigator-assessed duration of response (DoR)
Délai: Up to approximately two years

For patients who reached complete response (CR) or partial response (PR), Duration of Response (DoR) is defined as the time from the first CR or PR until disease progression or death due to any cause, whichever occurs first

Up to approximately two years
IRC- and investigator-assessed clinical benefit rate (CBR)
Délai: Up to approximately two years

Defined as the ratio of patients with complete response (CR), partial response (PR), or stable disease (SD)

Up to approximately two years
IRC- and investigator-assessed time to response (TTR)
Délai: Up to approximately two years

Time To Response (TTR) is defined as the time from the start of treatment to the first objective response rate (ORR)

Up to approximately two years
Safety Endpoints
Délai: Up to approximately two years
  • Incidence and severity of treatment-emergent adverse events (TEAEs), incidence of treatment-emergent serious adverse events (TESAEs), incidence of TEAEs leading to permanent discontinuation, dose interruption, and dose reduction, and their correlation to study drug. The severity is determined according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 6.0 (NCI CTCAE 6.0).
  • Changes in laboratory tests, vital signs, 12-lead ECG, etc.
Up to approximately two years
PK characteristics of HMPL-760 in patients with R/R DLBCL when administered in combination with R-GemOx
Délai: At the end of Cycle 4 (each cycle is 21 days)]

including but not limited to steady-state plasma concentrations of HMPL-760 pre-dose [trough concentrations (Ctrough)] and post-dose (C1h and C2h); If possible, a population pharmacokinetic (PPK) model can be used to generate PK parameters. If necessary, it can also be combined with other studies for model analysis.

If possible, a population pharmacokinetic (PPK) model can be used to generate PK parameters. If necessary, it can also be combined with other studies for model analysis.

At the end of Cycle 4 (each cycle is 21 days)]

Autres mesures de résultats

Mesure des résultats
Description de la mesure
Délai
Biomarker assessment
Délai: Up to approximately two years

Detect tumor driver gene mutations in tissue and blood samples, such as MYD88 and CD79B, etc, and explore the relationship between their mutation status and drug efficacy.

Up to approximately two years
To explore the metabolite profile of HMPL-760 in combination with R-GemOx in tumor patients
Délai: Up to approximately two years

Human metabolites of HMPL-760 when co-administered with R-GemOx

Up to approximately two years
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
Délai: Up to approximately two years

maximum concentration in steady-state (Cmax,ss)

Up to approximately two years
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
Délai: Up to approximately two years

time to maximum concentration in steady-state (Tmax,ss)

Up to approximately two years
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
Délai: Up to approximately two years

Area Under the Curve at steady state refers to the area under the plasma concentration-time curve during a dosing interval at steady state conditions (AUC,ss)

Up to approximately two years
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
Délai: Up to approximately two years

The rate at which the drug is eliminated from the body (CL/F) (if applicable )

Up to approximately two years
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
Délai: Up to approximately two years

The distribution volume calculated based on the terminal elimination phase (Vz/F )(if applicable)

Up to approximately two years

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Les enquêteurs

  • Chercheur principal: Weili Zhao, Ruijin Hospital

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

20 mars 2026

Achèvement primaire (Estimé)

30 avril 2028

Achèvement de l'étude (Estimé)

30 décembre 2028

Dates d'inscription aux études

Première soumission

28 janvier 2026

Première soumission répondant aux critères de contrôle qualité

6 février 2026

Première publication (Réel)

13 février 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

10 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

9 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner